Live Wire
|Latest Updates|Breaking News|
Live Wire Synced
|
|
Chronicle GlobalGlobal Live News & Entity Knowledge Graph
DEVELOPING

Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says

Martin Shkreli—the ex-pharmaceutical executive infamous for illegally hiking the price of a lifesaving anti-parasitic drug by more than 4,000 percent and gettin...

By Beth Mole•Oct 13, 2026, 10:48 PM UTC•1 min read
US
Share Dispatch
Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says
Key Developments & Executive Summary
  • Primary Wire Report: Martin Shkreli—the ex-pharmaceutical executive infamous for illegally hiking the price of a lifesaving anti-parasitic drug by more than 4,000 percent and gettin...
  • Desk & Verification: Normalized under Technology desk via Ars Technica.
  • Classification Status: DEVELOPING wire dispatches verified against institutional sources.

Martin Shkreli—the ex-pharmaceutical executive infamous for illegally hiking the price of a lifesaving anti-parasitic drug by more than 4,000 percent and getting a seven-year prison sentence for the fraudulent scheme he used to do it— has been under a lifetime ban from the pharmaceutical industry since 2022. However, according to the Federal Trade Commission and the attorneys general of seven states, Shkreli has "flagrantly and repeatedly" violated that ban nearly the entire time—allegedly by trading stock in dozens of drug companies and discussing the industry during livestreams on social media. On Tuesday, the FTC and the seven states asked a federal judge to hold Shkreli in contempt for the alleged violations. The states include New York, California, Illinois, North Carolina, Ohio, Pennsylvania, and Virginia—the same states that joined the FTC in suing Shkreli in 2020 over the "elaborate anticompetitive scheme" involving the anti-parasitic drug, Daraprim. The scheme raised the price from $17.50 per pill to $750 per pill virtually overnight, while blocking generic competitors from entering the market. Read full article Comments

Share Dispatch
B

Beth Mole

Contributor

Contributing Reporter via Ars Technica

Editorial Transparency

This article has been aggregated and formatted under Chronicle Global's editorial standards. Primary source reporting is attributed to originating news services and verified against public records.

Original Wire Source Release

Direct primary wire transmission originated by Ars Technica.

Read Original Primary Wire

Source Transparency & Verification Dossier

Primary Attribution

Ars Technica

View Original Wire / Document
Classification & Timestamp

Format: DEVELOPING

Retrieved / Published: Oct 13, 2026, 10:48 PM UTC

Content normalized through Chronicle Ingestion Engine.

Editorial Standards
Institutional Intelligence Dispatch

The Chronicle Morning Intelligence Briefing

Join 18,500+ global policy analysts, diplomats, and tech researchers. High-signal empirical dispatches delivered daily at 06:00 UTC.

•
Zero spam•18,500+ subscribers worldwide•1-click unsubscribe anytime

Related Coverage & Developing Updates